Multisciplinary management of patients with liver metastasis from colorectal cancer

Table 1 Response and resection rates from trials with first-line chemo/biologic therapy

Study	Selection	Treatment	Response	Resection
Van Cutsem et al[88] 2009	Unselected	Bevacizumab + chemotherapy (FOLFOX/FOLFIRI)	NA	11.8%
				6% (R0)
Okines et al[89] 2009	Unselected	Bevacizumab + Oxaliplatin-based chemotherapy	38%	6.3%
Wong et al[90] 2011	Unselected	Bevacizumab + XELOX	68%	48.0%
Loupakis et al[91] 2013	Unselected	Bevacizumab + FOLFOXIRI	64%	15.0%
Martin et al[92] 2014	Unselected	Bevacizumab + FOLFOX + DEBIRI	78%	35.0%
Bokemeyer et al[94] 2009	KRAS WT	Cetuximab + FOLFOX	57%	7.3%
				4.7 (R0)
Van Cutsem et al[95] 2011	KRAS WT	Cetuximab + FOLFIRI	57%	16.0%
				7% (R0)
Folprecht et al[22] 2010	KRAS WT	Cetuximab + chemotherapy (FOLFOX/FOLFIRI)	68%	43.0%
				34% (R0)
Garufi et al[96] 2010	KRAS WT	Cetuximab + FOLFOXIRI	79%	60.0%
Ye et al[97] 2013	KRAS WT	Cetuximab + FOLFOXIRI	57%	25% (R0)
Köhne et al[100] 2012	KRAS WT	Panitumumab + FOLFIRI	56%	15.0%
Douillard et al[101] 2010	KRAS WT	Panitumumab + FOLFOX	57%	27.0%
				5.2% (R0)
	NRAS WT	Panitumumab + FOLFOX		31.0%

NA: Not available.